Inspira Technologies OXY B.H.N. Ltd. announced financial results for the six-month period ending June 30, 2025. The company secured $49.5 million in purchase orders for its life-saving technologies, with 97.35% accuracy for the HYLA blood sensor. They also achieved over 99% gas exchange efficiency with their VORTX technology. Operating expenses increased to $7,235,000, reflecting growth and strategic initiatives. The company’s cash position was $2,126,000 as of June 30, 2025. With a focus on advanced respiratory care and real-time blood monitoring, Inspira Technologies is making significant strides in the medical device industry.

Inspira Technologies is a pioneer in advanced respiratory support and blood monitoring solutions, with a focus on life-saving technologies. The company’s recent achievements include securing $49.5 million in purchase orders, achieving high accuracy with the HYLA blood sensor, and attaining over 99% gas exchange efficiency with the VORTX technology. With a strategic focus on growth and innovation, Inspira Technologies is positioned as a transformative force in the medical device industry. Their commitment to saving lives and advancing healthcare technology sets them apart as a leader in the field.

Read more at GlobeNewswire: Inspira Technologies Reports First Half 2025 Financial